secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001641172-25-000525
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty
--------------------------------------------------------------------------------

- Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.
- Consideration: 1M restricted shares (~16% dilution) plus 10% net sales revenue.
- Term perpetual; if <$1.5M sales by Dec 2026, rights become non-exclusive; can extend 12 mo with $5M payment.
- Raised $200k via sale of 80k shares at $2.50/share to accredited investor.
- Clinical study: 14.3% reached HbA1c targets (vs 0% placebo); 83.3% reached SBP goals (vs 60%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/0001641172-25-000525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer